Author’s reply to the letter regarding “Serum adiponectin as a potential biomarker of therapeutic effect on cardiac metabolism in hypertensive patients with reduced ejection fraction”

Q: What does this research mean for the field?

Serum adiponectin serves as a potential biomarker for evaluating therapeutic effects on cardiac metabolism in hypertensive patients with reduced ejection fraction. Novelty: ClaimNovelty.INCREMENTAL. Consensus alignment: ConsensusAlignment.NEUTRAL.

Haruhito Harada; Hisashi Kai

doi:10.1038/s41440-026-02854-8

October 20, 2026Hypertension Research

Author’s reply to the letter regarding “Serum adiponectin as a potential biomarker of therapeutic effect on cardiac metabolism in hypertensive patients with reduced ejection fraction”

View at Publisher

Ask AI

Bookmark

Share

Key result

Serum adiponectin tracks therapeutic effects on cardiac metabolism in hypertensive patients with HFrEF.

Key Points

Address and clarify clinical inquiries regarding the utility of serum adiponectin as a biomarker for assessing cardiac metabolic responses to treatment in hypertensive patients with heart failure.
Correspondence synthesis and author rebuttal evaluating clinical questions raised on biomarker validity and therapeutic response.
Review of metabolic pathway alterations in hypertensive patients with reduced ejection fraction.
Maintains the role of circulating adiponectin as a relevant metabolic indicator during cardiac therapy.
Clarifies methodological and patient-selection nuances in interpreting cardiac metabolic recovery.

Ask about this paper

Answers are grounded in this paper and cite their sources.

Implication

May support adiponectin as metabolic indicator in treated hypertensive HFrEF; leaves clinical adoption open pending validation.

Abstract

Hypertension Research - Author’s reply to the letter regarding “Serum adiponectin as a potential biomarker of therapeutic effect on cardiac metabolism in hypertensive patients with...

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Harada et al. (2026) studied this question. Serum adiponectin is evaluated as a potential biomarker of therapeutic effect on cardiac metabolism in hypertensive patients with reduced ejection fraction.

synapsesocial.com/papers/6ad8b08b88dba358f6c89342 https://doi.org/10.1038/s41440-026-02854-8

View at Publisher

Ask AI

Bookmark

Share

Author’s reply to the letter regarding “Serum adiponectin as a potential biomarker of therapeutic effect on cardiac metabolism in hypertensive patients with reduced ejection fraction”

Key Points

Ask about this paper

Implication

Abstract

Discussion

Cite This Study

Author’s reply to the letter regarding “Serum adiponectin as a potential biomarker of therapeutic effect on cardiac metabolism in hypertensive patients with reduced ejection fraction”

Key Points

Ask about this paper

Implication

Abstract

Discussion

Cite This Study

Keep reading

Keep reading